Moroccan pharmaceutical company Laprophan, one of Africa’s largest, has recorded strong investor interest in its initial public offering, with preliminary demand reaching 15.3 billion dirhams, about seven times the size of the offer, according to Moroccan media.
More than 44,000 subscribers took part in the operation, reflecting significant market enthusiasm for the laboratory’s listing on the Casablanca Stock Exchange.
The figures, based on initial reports from the placement syndicate at the end of the subscription period, remain provisional.
The Casablanca Stock Exchange was scheduled to centralise and consolidate the orders on 19 November, with definitive results to be announced on 25 November during the company’s first trading ceremony.
The IPO has a maximum size of 2.22 billion dirhams and combines a capital increase of 4,105,500 new shares with the sale of 2,412,200 existing shares.
The subscription price was set at 341 dirhams per share.
The primary objective of the listing is to finance the full acquisition of Corporate Investment Holding, the parent company of laboratory Polymedic.


